tumor in the light of the revised SIOP-01 classification

78
Patients with persistent hypertension need chronic
pharmacotherapy based on α and β receptor antagonists. Calcium
channel blockers also manage an effective blood pressure
control without overshoot and orthostatic hypotension
[2-5, 12, 28]. In case of intolerance or resistance to α-blockers
α-methylparatyrosine can be used to decrease tumor catecholamine
production [2, 28]. There are also some clinical
experiences with unlabeled somatostatin analogues, but the
first results are not promising and no tumor regression or hormone
level reduction were observed [28].
Follow-up
Long term, lifetime follow-up is necessary in all patients with
pheochromocytoma because recurrent disease or distant metastases
can develop even more than 15–20 years after successful
resection of apparently benign primary tumor [6, 8,
10, 12, 13, 27, 28]. Follow-up should include blood pressure
References
1. Averbach SD, Steakley CS, Young RN,
et al (1988) Malignant pheochromocytoma:
effective treatment with a combination
of cyclophosphamide, vincristine
and dacarbazine. Ann Intern Med
109: 267–273
2. Bravo EL (1994) Evolving concepts in
the pathophysiology, diagnosis and treatment
of pheochromocytoma. Endocr
Rev 15: 356–368
3. Bravo EL (2004) Pheochromocytoma:
current perspectives in the pathogenesis,
diagnosis and management. Arq
Bras endocrinol Metab 48: 746–750
4. Bravo EL, Tagle R (2003) Pheochromocytoma:
state-of-the-art and future
prospects. Endocr Rev 24: 539–553
5. Ciftci AO, Tanyel FC, Senocak ME,
Buyukpamukcu N (2001) Pheochromocytoma
in children. J Pediatr Surg 36:
447–452
6. Eisenhofer G, Bornstein SR, Brouwers
FM, et al (2004) Malignant pheochromocytoma:
current status and initiatives
for future progress. Endocrine-Related
Cancer 11: 423–436
7. European Association of Nuclear Medicine
(2003) Guidelines for 131 I–metaiodobenzylguanidine
therapy. Eur J
Nucl Med 30: BP23–BP26
8. Fitzgerald PA, Goldfien A (2004) Adrenal
Medulla. In: Greenspan FS, Gardner
DG (Eds) Basic and clinical endocrinology.
Lange Medical Books/
McGraw-Hill New York, pp 439–477
9. Garaventa A, Gambini C, Villavecchia
G, et al (2003) Second malignancies in
children with neuroblastoma after combined
treatment with 131 I-metaiodobenzylguanidine.
Cancer 97: 1332–1338
10. Goldstein RE, O’Neill JA, Holcomb
GW, et al (1999) Clinical experience
over 48 years with pheochromocytoma.
Ann Surg 229: 755–766
11. Hoefnagel CA, Schornagel J, Valdes
Olmos RA (1991) 131 I-metaiodobenzylguanidine
therapy of malignant pheochromocytoma:
interference of medication.
J Nucl Biol Med 35: 308–312
12. Januszewicz W, Jarz¹b B, Januszewicz
A, Prejbisz A (2005) Malignant pheochromocytoma.
Arterial Hypertension
9: 132–140 (in Polish)
13. Januszewicz W, Prejbisz A, Januszewicz
A, Pêczkowska M (2002) guz
chromoch³onny-choroba o wielu obliczach.
Arterial Hypertension 6:
217–227 (in Polish)
14. Januszewicz W, Wocial B, Chodakowska
J et al. (1991) Z³oœliwy guz chromoch³onny.
Pol Tyg Lek 48: 664–667
(in Polish)
15. Kaltas G, Mukherjee JJ, Plowman PN,
Grossman AB (2001) The Role of chemotherapy
in the nonsurgical management
of malignant neuroendocrine tumours.
Clin Endocrinol 55: 575–587
16. Kaufman BH, Telander RL, van Heerden
JA, Zimmerman D, Sheps SG,
Dawson B (1983) Pheochromocytoma
an the pediatric age group: current status.
J Pediatr Surg 18: 879–884
measurement, biochemical tests and imaging studies. The first
evaluation of plasma metanephrine level or 24-hour urine collection
for fractionated catecholamines, metanephrines is recommended
approximately 2–6 weeks after the operation [8,
22]. The next examinations should be obtained quarterly during
the first year after surgery and further annually [6, 8]. Serum
chromogranin-A can be also a good tumor marker, but
only in patients with normal renal function [2, 4, 8]. Imaging
procedures including computed tomography (CT), magnetic
resonance imaging (MRI), 131 I or 123 I MIBG scintigraphy and
new modalities such as somatostatin receptor scintigraphy or
positron emission tomography (PET) should be performed on
the basis of biochemical test findings [22].
Concluding, successful treatment of malignant pheochromocytoma
still remains a challenge for scientists and clinicians.
Further investigations of genetic predispositions,
new molecular prognostic markers and new therapeutical approaches
are required.
17. Konings JE, Bruning PF, Abeling NG,
van Gennip AH, Hoefnagel CA (1990)
Diagnosis and treatment of malignant
pheochromocytoma with 131 I-metaiodobenzylguanidine:
a case report. Radiotherapy
and Oncology 17: 103–108
18. Lam MG, Lips CJ, Jager PL, et al
(2005) Repeated 131 I-metaiodobenzylguanidine
therapy in two patients with
malignant pheochromocytoma. J Clin
Endocrinol Metab 90: 5888–5895
19. Lio S, Napolitano G, Giuliani C, et al
(1991) A overview on the management
of malignant pheochromocytoma. J
Nucl Biol Med 35: 263–265
20. Mukherjee JJ, Kaltas GA, Islam N, et al
(2001) Treatment of metastatic carcinoids
tumours, pheochromocytoma, paraganglioma
and nedullary thyroid carcinoma
of the thyroid with 131 I-metaiodobenzylguanidine.
Clin Endocrinol 55:
47–60
21. Neumann DR, Bausch B, McWhinney
SR, et al (2002) Germ-line mutations in
nonsyndromic pheochromocytoma. N
Engl J Med 346: 1459–466
22. Pacak K, Linehan WM, Eisenhofer G,
Mc Clellan MW, Goldstein DS (2001)
Recent Advances in genetics, diagnosis,
localization and treatment of pheochromocytoma.
Ann Intern Med 134:
315–329
23. Pham TH, Moir Ch, Thompson GB, et
al (2006) Pheochromocytoma and paraganglioma
in children: a review of medical
surgical management at a tertiary
care center. Pediatrics 118: 1109–1117